Overview
Legal name
AKAZA BIOSCIENCE LIMITED
Region
Unknown
Registered address
Unknown
Insolvency history
No
Company
Active
LTD
Company profile
AKAZA Bioscience Limited
Home - Akaza Bioscience
AKAZA Bioscience Limited is a UK company with status active founded in 2018.
CRN
11366292
Founded
2018
Age
7
Corporate ownership
Updated 06 Jun 2026 16:52
1 level
1 ultimate controller
1
Company
Active
LTD
AKAZA Bioscience Limited
CRN 11366292
2
Direct and ultimate controller
Active
LTD
Aquarius Bio Limited
CRN 13293372
Company events
Reference milestones and recent Companies House filing stream events.
3 events
25 Sep
2024
Accounts With Accounts Type Total Exemption Full
Accounts Awaiting analysisAA | Transaction MzQzNzIyMDU0MWFkaXF6a2N4
Published 25 Sep 2024 03:30
25 Sep
2024
Change Account Reference Date Company Previous Extended
Accounts Awaiting analysisAA01 | Transaction MzQzNzIyMDE4NWFkaXF6a2N4
Published 25 Sep 2024 03:27
16 May
2018
Incorporated
InceptionCompany registered at Companies House
Public funding
2 awards
First funded
2019
Funded years
2019, 2020
Age at first award
0 years
Projects
2020
Feasibility Studies
Lead participant
Proof of Concept clinical trial for Akaza Biosciences’ Resatorvid in Acute on Chronic Liver Failure patients
1 Jun 2020 to 30 Nov 2020
Awarded
£160,398
Total cost £229,140
no public description
2019
Collaborative R&D
Lead participant
Proof of Concept clinical trial for Akaza Biosciences’ Resatorvid in Acute on Chronic Liver failure patients
1 Apr 2019 to 31 Aug 2021
Awarded
£2,671,549
Total cost £3,816,499
Acute-on-chronic liver failure (ACLF) is a syndrome characterized by acute deterioration of existing chronic liver disease, progressing to organ failure and associated with a high mortality. It usually results after a precipitating event such as trauma, surgery, variceal bleeding, or infection that may directly exaggerate liver injury. There are no approv...
Product types
Collaborative R&D
Feasibility Studies